製品名:(S)-4-Oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylic acid

IUPAC Name:(6S)-4-oxo-4H,6H,7H,8H-pyrrolo[1,2-a]pyrimidine-6-carboxylic acid

CAS番号:1190392-22-3
分子式:C8H8N2O3
純度:95%+
カタログ番号:CM556749
分子量:180.16

包装単位 有効在庫 価格(USD) 数量
CM556749-50mg in stock ȡƦȐ
CM556749-100mg in stock Ƕŵŵ
CM556749-250mg in stock ȺũȺ
CM556749-1g in stock ȡũƎȐ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1190392-22-3
分子式:C8H8N2O3
融点:-
SMILESコード:O=C([C@@H]1CCC2=NC=CC(N21)=O)O
密度:
カタログ番号:CM556749
分子量:180.16
沸点:
MDL番号:
保管方法:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Pyrrolidines
Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

Column Infos

Vibegron
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of OBGEMSA (vibegron under the international non-proprietary name) for the symptomatic treatment of adult patients with overactive bladder syndrome (OAB).
Vibegron is a novel, potent, and selective human beta-3 adrenergic receptor (β3-AR) agonist. Beta receptors are found throughout the body, but β3-ARs are predominantly found on human detrusor smooth muscle. β3-ARs agonists bind to and activate beta-3 receptors on the detrusor muscle, leading to relaxation of the detrusor muscle to increase vesical capacity and to reduce OAB symptoms.